Masimo SET Pulse Oximetry Demonstrates Accuracy Across Skin Tones in Newborns
Masimo, a global medical technology company, has announced the results of a study evaluating the accuracy of its SET pulse oximetry technology in critically ill neonates. The study, known as the NeoPODS, was conducted at the University of California, Davis, and the University of Mississippi, Jackson. It found that the Masimo SET pulse oximetry showed less than 1% overall statistical bias and no clinically meaningful discrepancies related to skin pigmentation. The study involved 100 newborns and used rigorous methods to ensure accurate results, including objective skin pigmentation classification and tightly paired SpO2-SaO2 measurements. The findings were presented at the Pediatric Academic Society and published in the Journal of Pediatrics. 
